-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
According to the draft recommendation guidelines issued by the British regulatory agency, the drug has been approved in December last year for the treatment of CLL patients with 17p deletion or TP53 mutation, or fludarabine combined with cyclophosphamide and rituximab (FCR), and bendumustine combined with rituximab (BR).
Calquence's NICE recommendation in the United Kingdom will provide this type of patient with a new treatment option other than chemotherapy, which is especially helpful during the COVID-19 pandemic.
In November last year, the European Medicines Agency (EMA) approved Calquence as a monotherapy or in combination with Roche Gazyvaro (obinutuzumab) for previously untreated and relapsed or refractory CLL patients.
Reference source:
1.
2.
3.
